evipedia.ai
← Back

Dandelion Root to Treat Cancer

Created on 10/23/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Dandelion root, an herb sold as tea, capsules and extracts, draws attention as a possible cancer treatment. Its water extract kills cancer cells in laboratory dishes and slows tumors in mice, but human evidence is a handful of leukemia reports where chemotherapy and other remedies often cloud the cause. It is an unproven add-on whose benefit in people is unknown and whose biggest hazard is displacing treatments that work. (Full Review)

Protocol

Regulatory traditional-use dose
1–5 g dried root, 2–3 times daily
Root simmered in 150 mL water; for digestive, appetite and urinary uses, not cancer
Windsor tea regimen
Three cups of root tea daily
Used by leukemia patients in case reports; no oncology guideline or completed trial defines a cancer dose
Best time of day
Morning to afternoon
Avoids nighttime urination; ½ hour before meals for appetite; no cancer data
Time to effect
Blood-count remission in myelomonocytic leukemia
Weeks to months
Reported case remissions after starting tea; unknown in controlled studies
Increased urine output
Within 5 hours of first dose
Rise in urination concentrated in this window; fresh-leaf extract, not root

Benefits

Contraindications
  • Hypersensitivity to dandelion or other plants of the Asteraceae family
  • Bile-duct obstruction, cholangitis, gallstones, liver disease or other biliary disease
  • People told by a physician to restrict fluid intake
  • Pregnant or breastfeeding women
  • Children under 12 years
  • Transplant recipients on cyclosporine, tacrolimus or sirolimus without drug-level monitoring
  • People with curable cancers using it in place of recommended treatment
    •
Key Interactions
  • Calcineurin and mTOR inhibitors (cyclosporine, sirolimus): Caution
  • Tyrosine kinase inhibitors (imatinib): Caution (theoretical)
  • CYP1A2 substrates (theophylline): Monitor (theoretical)
  • UGT-cleared drugs (irinotecan): Monitor (theoretical)
  • Quinolone antibiotics (ciprofloxacin): Caution (theoretical)
  • Diuretics and lithium (furosemide): Monitor (theoretical)
  • Glucose-lowering drugs (insulin): Monitor (theoretical)
  • Potassium-raising drugs (spironolactone; ACE inhibitors): Monitor (theoretical)
  • Chemotherapy (paclitaxel): Monitor (theoretical)
  • Over-the-counter caffeine and diuretics (pamabrom): Monitor (theoretical)
  • Diuretic supplements (horsetail): Monitor (theoretical)
  • Glucose-lowering supplements (berberine): Monitor (theoretical)
  • Daisy-family herbs (chamomile): Caution in sensitized people (theoretical)
  • Other interventions (radiotherapy, surgery): Monitor (theoretical)
    •

Risk & Side Effects

  • High:
  • Medium:
  • Low: Delayed or forgone effective cancer treatment; allergic and contact skin reactions; altered levels of narrow-margin drugs; digestive upset; low blood sugar; liver and bile-flow injury; oxalate injury with very high intake
    •
  • Speculative: Estrogen-like stimulation of hormone-sensitive tumors; lower peak antibiotic levels; contaminated products
    •

Monitoring

Marker Target Why
Complete blood count with differential White cells 4.0–11.0 × 10⁹/L; monocytes 0.2–1.0 × 10⁹/L Blood-cancer readout
Tumor-specific markers and imaging No established target; change from own baseline Disease burden
ALT, AST, alkaline phosphatase, bilirubin ALT 7–56 U/L; AST 10–40 U/L; alkaline phosphatase 44–147 U/L; bilirubin 0.1–1.2 mg/dL Safety check: stop if rising
Serum potassium 3.5–5.0 mmol/L Safety check: high potassium
Serum creatinine 0.6–1.3 mg/dL Safety check: kidney function
Fasting glucose 70–99 mg/dL Safety check: low blood sugar
Trough levels of narrow-margin drugs (cyclosporine, sirolimus) No established target for this use; prescriber's individual target Safety check: changes dosing

Cadence: Baseline panel before starting; at 2 weeks (drug levels, glucose, potassium), at 6 weeks, then every 3 months alongside routine oncology visits

Qualitative Assessment

  • Appetite and digestion (gas, bloating)
  • Urination frequency, especially at night
  • Skin rash, itching or wheeze after use
  • Symptoms of low blood sugar (shakiness, sweating)
  • Yellowing of skin or eyes, dark urine or itching
  • Energy, fatigue and overall well-being during cancer treatment
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.